Viking Therapeutics Inc.
Rating
Updated: Aug 19, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investi...
Latest News
5 days ago · fool.com
Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic.VK2735's dual formulation and rapid weight loss onset could be key differentiators provided the phase 3 trials are successful. Tolerability and trial design adjustments are crucial for oral VK2735's success.
5 days ago · zacks.com
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to NoteThe latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $29.52, representing a -1.44% change from its previous close.
6 days ago · benzinga.com
What's Going On With the Dip in Viking Therapeutics Stock?Viking Therapeutics Inc. (NASDAQ:VKTX) shares are dropping Tuesday amid a broader risk-off session, even though the stock's longer-term uptrend and its sector's strength both remain intact.
8 days ago · seekingalpha.com
Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptViking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
11 days ago · zacks.com
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
12 days ago · zacks.com
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for InvestorsViking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.13, moving 1.74% from the previous trading session.
13 days ago · zacks.com
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to KnowViking Therapeutics, Inc. (VKTX) closed at $32.7 in the latest trading session, marking a -2.91% move from the prior day.
19 days ago · zacks.com
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to KnowViking Therapeutics, Inc. (VKTX) closed at $33.98 in the latest trading session, marking a +1.43% move from the prior day.
19 days ago · fool.com
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're WrongViking Therapeutics' shares could soar as it makes progress with its leading candidates. However, the stock will only triple under the most optimistic assumptions.
20 days ago · prnewswire.com
Viking Therapeutics to Participate at Upcoming Investor ConferencesSAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Annual Cantor Global Health Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the Bernstein 3rd Annual Healthcare Forum in September.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove VKTX